Stockwatch: Some Failed Drugs Never Die, They Just Find New Investors
Cytokinetics and Synairgen Are Cases In Point
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
You may also be interested in...
Single Trial, Missing Companion Diagnostic May Be Insurmountable Hurdles for Cytokinetics Heart Failure Drug
Cytokinetics willingness to tweak the indication for omecamtiv mecarbil doesn’t look likely to help the drug get past a handful of safety and efficacy concerns at its 13 December advisory panel.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.